Who Pays My Doctor?

Healthcare provider profile · identity verified

Matthew J Budoff, M.D.

Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · TORRANCE, CA · NPI 1811967433

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Matthew J Budoff, M.D. received $541,709.23 in general payments during 2025 across 454 reported records.

HEARTFLOW, INC. accounted for 18.3% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 23 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$541,709.23

454 reported records · 24 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
HEARTFLOW, INC. Unresolved — no canonical attribution shown $99,009.7518.3%702025
Novo Nordisk Inc Unresolved — no canonical attribution shown $87,918.2316.2%432025
Regeneron Healthcare Solutions, Inc. Unresolved — no canonical attribution shown $74,497.5313.8%542025
Bayer Healthcare Pharmaceuticals Inc. Unresolved — no canonical attribution shown $67,900.4512.5%522025
Lilly USA, LLC Unresolved — no canonical attribution shown $51,933.019.6%462025
Amgen Inc. Unresolved — no canonical attribution shown $51,853.429.6%602025
Boehringer Ingelheim Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $21,276.753.9%292025
AstraZeneca Pharmaceuticals LP Unresolved — no canonical attribution shown $20,431.023.8%202025
Amarin Pharma, Inc. Unresolved — no canonical attribution shown $15,338.832.8%172025
Merck Sharp & Dohme LLC Unresolved — no canonical attribution shown $10,838.522.0%102025
Ionis Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $10,207.471.9%82025
Corcept Therapeutics Unresolved — no canonical attribution shown $8,410.861.6%122025
ABBVIE INC. Unresolved — no canonical attribution shown $7,251.831.3%82025
AGEPHA Pharma FZ LLC Unresolved — no canonical attribution shown $6,524.341.2%32025
Novartis Pharmaceuticals Corporation Unresolved — no canonical attribution shown $3,237.030.6%72025
Cleerly, Inc. Unresolved — no canonical attribution shown $3,025.420.6%62025
FUKUDA DENSHI Co., Ltd. Unresolved — no canonical attribution shown $1,500.000.3%12025
Boston Scientific Corporation Unresolved — no canonical attribution shown $174.000.0%12025
Medtronic, Inc. Medtronic, Inc.
exact · evidence 2025-07-22 		$166.740.0%12025
GE HEALTHCARE Unresolved — no canonical attribution shown $100.000.0%12025
PFIZER INC. Unresolved — no canonical attribution shown $34.480.0%22025
Invivyd Inc Unresolved — no canonical attribution shown $31.360.0%12025
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) Unresolved — no canonical attribution shown $25.850.0%12025
BridgeBio Pharma, Inc. Unresolved — no canonical attribution shown $22.340.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$413,669.19113
Consulting Fee$75,679.5032
Travel and Lodging$41,080.14169
Food and Beverage$11,280.40140

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
FFRct
Normalized: ffrct		 Device HEARTFLOW, INC. $99,009.75 70 2025
Source payment records
Wegovy
Normalized: wegovy		 Drug Novo Nordisk Inc $69,581.23 34 2025
Source payment records
Kerendia
Normalized: kerendia		 Drug Bayer Healthcare Pharmaceuticals Inc. $67,900.45 52 2025
Source payment records
EVKEEZA
Normalized: evkeeza		 Biological Regeneron Healthcare Solutions, Inc. $67,165.18 51 2025
Source payment records
REPATHA
Normalized: repatha		 Biological Amgen Inc. $51,816.84 59 2025
Source payment records
ZEPBOUND
Normalized: zepbound		 Drug Lilly USA, LLC $44,733.85 30 2025
Source payment records
LOKELMA
Normalized: lokelma		 Drug AstraZeneca Pharmaceuticals LP $20,431.02 20 2025
Source payment records
Vascepa
Normalized: vascepa		 Drug Amarin Pharma, Inc. $15,338.83 17 2025
Source payment records
JARDIANCE
Normalized: jardiance		 Drug Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC $11,146.44 10 2025
Source payment records
OLEZARSEN
Normalized: olezarsen		 Drug Ionis Pharmaceuticals, Inc. $10,207.47 8 2025
Source payment records
Korlym
Normalized: korlym		 Drug Corcept Therapeutics $8,410.86 12 2025
Source payment records
Ozempic
Normalized: ozempic		 Drug Novo Nordisk Inc $7,222.00 3 2025
Source payment records
LODOCO
Normalized: lodoco		 Drug AGEPHA Pharma FZ LLC $6,524.34 3 2025
Source payment records
LEQVIO
Normalized: leqvio		 Drug Novartis Pharmaceuticals Corporation $3,237.03 7 2025
Source payment records
VS-2000
Normalized: vs 2000		 Device FUKUDA DENSHI Co., Ltd. $1,500.00 1 2025
Source payment records
Cleerly Ischemia
Normalized: cleerly ischemia		 Device Cleerly, Inc. $320.57 4 2025
Source payment records
Cleerly Labs
Normalized: cleerly labs		 Device Cleerly, Inc. $320.57 4 2025
Source payment records
General - Ultrasound
Normalized: general ultrasound		 Device Boston Scientific Corporation $174.00 1 2025
Source payment records
SYMPLICITY G3
Normalized: symplicity g3		 Device Medtronic, Inc. $166.74 1 2025
Source payment records
VYNDAQEL
Normalized: vyndaqel		 Drug PFIZER INC. $34.48 2 2025
Source payment records
PEMGARDA
Normalized: pemgarda		 Biological Invivyd Inc $31.36 1 2025
Source payment records
LifeVest
Normalized: lifevest		 Device ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $25.85 1 2025
Source payment records
Attruby
Normalized: attruby		 Drug BridgeBio Pharma, Inc. $22.34 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Rosuvastatin CalciumRosuvastatin Calcium4017
Atorvastatin CalciumAtorvastatin Calcium22suppressed
Repatha SureclickEvolocumab21suppressed
Metoprolol SuccinateMetoprolol Succinate19suppressed
Losartan PotassiumLosartan Potassium18suppressed
NexletolBempedoic Acid13suppressed
Amlodipine BesylateAmlodipine Besylate12suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $541,709.23 · 454 records HEARTFLOW, INC. Attruby, Cleerly Ischemia, Cleerly Labs, EVKEEZA, FFRct, General - Ultrasound, JARDIANCE, Kerendia, Korlym, LEQVIO, LODOCO, LOKELMA, LifeVest, OLEZARSEN, Ozempic, PEMGARDA, REPATHA, SYMPLICITY G3, VS-2000, VYNDAQEL, Vascepa, Wegovy, ZEPBOUND — —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error